TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24456703

Group type: EXPERIMENTAL
Intervention: IVF-eSET
Number of subjects: 116

Group type: COMPARATOR
Intervention: IUI-ovarian stimulation
Number of subjects: 116
Study: 22372543

Group type: EXPERIMENTAL
Intervention: Combined superficial & deep fractional skin treatment using a 120‐micron, focused CO(2) laser beam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined superficial & deep fractional skin treatment
Number of subjects: 15
Study: 21250576

Group type: EXPERIMENTAL
Intervention: 2‐step All Bond 3 (AB3‐2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 3‐step All Bond 3 (AB3‐3)
Number of subjects: 33
Study: 18418704

Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein isolation (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (group 2)
Number of subjects: 110
Study: 15708690

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 mg/day and salt 1 g/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 33
Study: 14645018

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 12
Study: 11053726

Group type: EXPERIMENTAL
Intervention: HIV patients after weight loss
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 27
Study: 8841834

Group type: EXPERIMENTAL
Intervention: niacinamide
Number of subjects: 72
Study: 1737735

Group type: EXPERIMENTAL
Intervention: Low-dose intranasal midazolam (0.25 to 0.5 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6390057

Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg to 100 micrograms/kg) + MPSS (30 mg/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bolus doses of naloxone (30 micrograms/kg) + continuous infusion (30 micrograms/kg/hr for 1 hour) + MPSS (30 mg/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Naloxone (bolus and continuous infusion) without MPSS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: MPSS alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Naloxone and corticosteroids (MPSS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low dose bolus and continuous infusion of naloxone + MPSS
Number of subjects: 57
Study: 30950300

Group type: EXPERIMENTAL
Intervention: Peer-facilitated intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (wait-listed)
Number of subjects: 23
Study: 29100644

Group type: EXPERIMENTAL
Intervention: Risk score for prolonged hospital length of stay after heart transplantation
Number of subjects: 16723

Group type: EXPERIMENTAL
Intervention: Risk model validation
Number of subjects: 16723
Study: 27011266

Group type: COMPARATOR
Intervention: Oral prednisolone 1 mg/kg/day, tapering by 5 mg/day, for 2 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrapolyp steroid injection (40 mg/mL triamcinolone, 1 mL) for up to five times with intervals of 1 week
Number of subjects: 90
Study: 24530944

Group type: EXPERIMENTAL
Intervention: hsCRP levels at admission
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: hsCRP levels at 48-72 hours
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: hsCRP levels at 30 days
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Admission hsCRP levels
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Higher admission hsCRP levels
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Higher hsCRP at 30 days among survivors
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: hsCRP increase at day 30 (>10% increase over baseline)
Number of subjects: 794
Study: 21947706

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily after EVL
Number of subjects: 43

Group type: COMPARATOR
Intervention: No antisecretory treatment
Number of subjects: 43
Study: 19411667

Group type: EXPERIMENTAL
Intervention: Phenylephrine at a rate of 16.6 microg min(‐1) (concentration 1 microg ml(‐1))
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ephedrine at a rate of 1.5 mg min(‐1) (concentration 90 microg ml(‐1))
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions (Phenylephrine and Ephedrine)
Number of subjects: 70
Study: 17311540

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: control group (C)
Number of subjects: 48
Study: 15188371

Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 190
Study: 11803993

Group type: EXPERIMENTAL
Intervention: Pulse-delay curing with a waiting time of at least 1 minute between exposures
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous-cure control
Number of subjects: 8
Study: 9930393

Group type: EXPERIMENTAL
Intervention: Psychotherapy in addition to corticosteroid treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Corticosteroid treatment alone (Control)
Number of subjects: 108
Study: 7850822

Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tissue-plasminogen activator
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (general)
Number of subjects: 62
Study: 3362340

Group type: EXPERIMENTAL
Intervention: Baseline condition with letters presented in their upright orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotated +90 degrees condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotated -90 degrees condition
Number of subjects: 0
Study: 29848776

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor (alogliptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Persistently high NT-proBNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Developed high NT-proBNP at 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: NT-proBNP remained low at both time points
Number of subjects: 0

Group type: COMPARATOR
Intervention: High NT-proBNP value at baseline that subsequently declined to low category
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absolute changes in NT-proBNP by 6 months
Number of subjects: 0
Study: 27272083

Group type: EXPERIMENTAL
Intervention: Naftifine cream 2%
Number of subjects: 231

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 231
Study: 25341903

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 88

Group type: COMPARATOR
Intervention: Early fasting
Number of subjects: 88
Study: 24071565

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg single dose)
Number of subjects: 0
Study: 19997688

Group type: EXPERIMENTAL
Intervention: General practice
Number of subjects: 107

Group type: COMPARATOR
Intervention: Hospital practice
Number of subjects: 107
Study: 18343652

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 IU, subcutaneously, once weekly) initiated within 7 days of the start of the first chemotherapy cycle
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard therapy (epoetin alfa when Hb <= 10 g/dL)
Number of subjects: 2
Study: 15633709

Group type: EXPERIMENTAL
Intervention: Patient with amusia
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1
Study: 12354473

Group type: EXPERIMENTAL
Intervention: Iron plus sulfadoxine‐pyrimethamine
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Iron alone
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine alone
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 10701699

Group type: EXPERIMENTAL
Intervention: Nevirapine 15 mg via short‐term i.v. infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nevirapine 50 mg tablet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nevirapine oral reference solution (50 mg/200 mL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg production‐line tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nevirapine oral reference solution (200 mg/200 mL)
Number of subjects: 36
Study: 8634003

Group type: EXPERIMENTAL
Intervention: Psychotherapy (cognitive, behavioral, brief psychodynamic, and group therapies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined psychotherapy-pharmacotherapy regimens
Number of subjects: 0
Study: 1773125

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bednets (500 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank formulation (similar to EC without permethrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lambda-cyhalothrin (25 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permethrin (5, 50, or 500 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 0
Study: 6764605

Group type: EXPERIMENTAL
Intervention: 100 mg SL-76188
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 175 mg SL-76188
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 250 mg SL-76188
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg D-amphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31293146

Group type: EXPERIMENTAL
Intervention: Observation with anticipation using ExoPinch finger robot
Number of subjects: 8

Group type: COMPARATOR
Intervention: Observation without anticipation
Number of subjects: 8
Study: 28382371

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5680

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5680

Group type: COMPARATOR
Intervention: Cangrelor vs Clopidogrel
Number of subjects: 5680
Study: 26122743

Group type: EXPERIMENTAL
Intervention: Piezosurgery Medical Device (experimental group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional 2-mm osteotome (control group)
Number of subjects: 22
Study: 23549769

Group type: EXPERIMENTAL
Intervention: Box Trainer
Number of subjects: 28

Group type: COMPARATOR
Intervention: VR Simulator
Number of subjects: 28
Study: 20589515

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg plus diazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo plus diazepam
Number of subjects: 120
Study: 19451213

Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (ET)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET)
Number of subjects: 55
Study: 15640298

Group type: EXPERIMENTAL
Intervention: NNT of 10
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: NNT of 100
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: NNT of 200
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: NNT of 400
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Side effects presented as headache
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Side effects presented as constipation
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Married respondents
Number of subjects: 2326
Study: 12879472

Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin (GC)
Number of subjects: 372

Group type: COMPARATOR
Intervention: mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP)
Number of subjects: 372
Study: 10386529

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) titrated from 100 mg/day over 6 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Phenytoin (PHT) titrated from 200 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 181
Study: 8885910

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol 2 mg alone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Combined therapy with norethisterone 1 mg
Number of subjects: 62
Study: 1369518

Group type: EXPERIMENTAL
Intervention: Live anesthetized dogs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cadavers
Number of subjects: 0
Study: 6405877

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with spontaneous ventilation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with spontaneous ventilation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with controlled ventilation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with controlled ventilation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group of orthopaedic patients
Number of subjects: 55
Study: 31770507

Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol implementation
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol compliance
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Platelets transfusion compliance
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate transfusion compliance
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Packed red blood cells transfusion compliance
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma transfusion compliance
Number of subjects: 1441
Study: 30293188

Group type: EXPERIMENTAL
Intervention: Glass fiber posts
Number of subjects: 38

Group type: COMPARATOR
Intervention: Titanium posts
Number of subjects: 38
Study: 28693520

Group type: EXPERIMENTAL
Intervention: Intervention arm with palliative care leaders in primary health care centers
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Usual care arm (control)
Number of subjects: 4640

Group type: EXPERIMENTAL
Intervention: Intervention arm with palliative care leaders
Number of subjects: 4640
Study: 25819484

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 3017

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3017
Study: 23000080

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 6 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: DASH diet for 6 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of aerobic exercise and DASH diet for 6 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 160
Study: 21784767

Group type: EXPERIMENTAL
Intervention: sPLA(2) activity measurement
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: N-terminal pro‐B‐type natriuretic peptide
Number of subjects: 3708

Group type: EXPERIMENTAL
Intervention: high‐sensitivity cardiac troponin T
Number of subjects: 3708
Study: 19412139

Group type: EXPERIMENTAL
Intervention: Freeze-dried femoral ring allograft (FD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Frozen femoral ring allograft (FZ)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 17563217

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combined CM and CBT
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tailored gay-specific version of CBT
Number of subjects: 145
Study: 16364829

Group type: EXPERIMENTAL
Intervention: BQ-123 (0.1, 0.2, and 0.3 mg/kg for 1 h)
Number of subjects: 11
Study: 12059866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and Brimonidine 0.2% (concomitant therapy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol/Brimonidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine and Timolol/Brimonidine (concomitant treatment)
Number of subjects: 20
Study: 10228816

Group type: EXPERIMENTAL
Intervention: Formal psychotherapeutic support in addition to routine care during the hospital stay
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard care provided on the surgical wards
Number of subjects: 271
Study: 8758126

Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (children without pulmonary disease)
Number of subjects: 27
Study: 1869979

Group type: EXPERIMENTAL
Intervention: Dipyridamole with low-level treadmill exercise
Number of subjects: 78

Group type: COMPARATOR
Intervention: Dipyridamole infusion alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Dipyridamole with isometric handgrip
Number of subjects: 78
Study: 6139346

Group type: EXPERIMENTAL
Intervention: 10 mg zetidoline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg zetidoline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg zetidoline
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2 mg haloperidol (positive control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30156479

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 665

Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 665
Study: 29737150

Group type: EXPERIMENTAL
Intervention: Pycnogenol® 150 mg/day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Antispasmina col forte (50 mg papaverine hydrochloride + 10 mg belladonna extract when needed)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Buscopan (10 mg when needed)
Number of subjects: 77
Study: 27207890

Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Suspend (PLGS) system
Number of subjects: 127
Study: 23582234

Group type: EXPERIMENTAL
Intervention: Neonatal glutamine supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no glutamine supplementation)
Number of subjects: 65
Study: 22374556

Group type: EXPERIMENTAL
Intervention: DL-alpha-lipoic acid (ALA) 300, 600, 900, and 1200 mg/day for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DL-alpha-lipoic acid (ALA)
Number of subjects: 38
Study: 20131188

Group type: EXPERIMENTAL
Intervention: Successful electrical cardioversion (EC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Persistent AF
Number of subjects: 43
Study: 16530916

Group type: EXPERIMENTAL
Intervention: Specialist nurse supported discharge
Number of subjects: 111

Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 111
Study: 17038827

Group type: EXPERIMENTAL
Intervention: Nasal, inactivated trivalent influenza virus vaccine (7.5, 15, or 30 microg hemagglutinin antigen)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nasal, inactivated trivalent influenza virus vaccine (30 microg hemagglutinin antigen)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12180373

Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study: 10486372

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) and endoscopy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Endoscopy alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment after evaluation with EUS and endoscopy
Number of subjects: 61
Study: 7496979

Group type: EXPERIMENTAL
Intervention: Single-zone 6.0-millimeter ablations
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Two-zone ablations
Number of subjects: 80
Study: 2127723

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) during the immediate postoperative period (Group I)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional serum therapy during the immediate postoperative period (Group II)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 27
Study: 145840

Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (1 to 4 mg intramuscularly)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Haloperidol (2 mg intramuscularly) or Sulpiride (100 mg intramuscularly) pretreatment
Number of subjects: 4
Study: 29745434

Group type: EXPERIMENTAL
Intervention: Synchronized transcutaneous electroacupuncture (STEA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study: 30650286

Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional hypoglycemic therapy
Number of subjects: 180
Study: 25096175

Group type: EXPERIMENTAL
Intervention: Interlaminar decompression
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Concomitant fusion
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Spondylolisthesis
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Spinal instability
Number of subjects: 106
Study: 23200158

Group type: EXPERIMENTAL
Intervention: Peer aggression (PA) class
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Peer aggression + peer victimization (PAPV) class
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Multiple domains of violence (MDV) class
Number of subjects: 694

Group type: COMPARATOR
Intervention: Comparison of PAPV class to MDV class
Number of subjects: 694
Study: 19404655

Group type: EXPERIMENTAL
Intervention: Mammotome (MT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: ATEC (A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both systems (MT and A)
Number of subjects: 62
Study: 18472356

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus adjuvant chemotherapy (CRT)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 316
Study: 15684293

Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14755361

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs
Number of subjects: 0
Study: 10373049

Group type: EXPERIMENTAL
Intervention: Sodium restricted (SR) diet for 5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet (C) for 5 days
Number of subjects: 8